Follow POL on Twitter On the question of whether FDA labeling requirements should preempt state tort law claims, which Michael Krauss raised this morning (welcome to the Forum Michael!), my Manhattan Institute colleague Bob Goldberg had this to say in today's Washington Times.
More on the FDA preemption question
Related Entries:
- Update on California foreign policy efforts
- Greg Conko: Can brand makers be sued for generic drug injuries?
- Romney and self-deporting
- Greg Conko discusses the FDA's ban on off-label promotion
- Another lawless jackpot award over propofol in Nevada
- Douglas v. Independent Living Center of Southern California
- Rehearing sought in Mensing
- Around the web, June 5
- Somin on federalism and tort reform
- Martin Act abuses
- "Abnormal Use" interview
- Lasker on preemption
- Around the web, March 28
- Teva and Baxter appeal $505 million Nevada propofol verdict
- Breaking: unanimous vote against preemption in Williamson v. Mazda
 |
| Isaac Gorodetski Project Manager, Center for Legal Policy at the Manhattan Institute igorodetski@manhattan-institute.org |
 |
| Laura Eyi Press Officer, Manhattan Institute leyi@manhattan-institute.org |
